BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 20378672)

  • 1. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
    Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
    J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
    Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin.
    Brinch KS; Tulkens PM; Van Bambeke F; Frimodt-Møller N; Høiby N; Kristensen HH
    J Antimicrob Chemother; 2010 Aug; 65(8):1720-4. PubMed ID: 20534628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal activity of quinupristin-dalfopristin against strains of Staphylococcus aureus with the MLS(B) phenotype of resistance according to the erm gene type.
    Clarebout G; Nativelle E; Bozdogan B; Villers C; Leclercq R
    Int J Antimicrob Agents; 2004 Nov; 24(5):444-9. PubMed ID: 15519475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis.
    Lemaire S; Kosowska-Shick K; Julian K; Tulkens PM; Van Bambeke F; Appelbaum PC
    Clin Microbiol Infect; 2008 Aug; 14(8):766-77. PubMed ID: 18727801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
    Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
    Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.
    Zarrouk V; Bozdogan B; Leclercq R; Garry L; Feger C; Carbon C; Fantin B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1244-8. PubMed ID: 11257041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of quinupristin/dalfopristin versus vancomycin, alone or in combination with rifampicin, against methicillin-resistant Staphylococcus aureus in a rabbit arthritis model.
    Hamel A; Caillon J; Jacqueline C; Batard E; Potel G
    Int J Antimicrob Agents; 2008 Feb; 31(2):158-60. PubMed ID: 18006281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
    Jørgen B; Merckoll P; Melby KK
    Scand J Infect Dis; 2007; 39(11-12):1059-62. PubMed ID: 17852934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of quinupristin/dalfopristin, levofloxacin and moxifloxacin against fusidic acid and rifampicin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) from Malaysian hospitals.
    Norazah A; Lim VK; Rohani MY; Kamel AG
    Med J Malaysia; 2005 Oct; 60(4):411-5. PubMed ID: 16570701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
    Drago L; Nicola L; De Vecchi E
    Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [MIC and MBC of quinupristin/dalfopristin of erythromycin-resistant MRSA strains isolated from clinical specimens].
    Młynarczyk G; Młynarczyk A; Szymanek K; Bilewska A; Pupek J; Luczak M
    Med Dosw Mikrobiol; 2006; 58(3):199-205. PubMed ID: 17340994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
    Sambatakou H; Giamarellos-Bourboulis EJ; Grecka P; Chryssouli Z; Giamarellou H
    J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subinhibitory quinupristin/dalfopristin attenuates virulence of Staphylococcus aureus.
    Koszczol C; Bernardo K; Krönke M; Krut O
    J Antimicrob Chemother; 2006 Sep; 58(3):564-74. PubMed ID: 16895938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage.
    Alós JI; García-Cañas A; García-Hierro P; Rodríguez-Salvanés F
    J Antimicrob Chemother; 2008 Oct; 62(4):773-5. PubMed ID: 18552338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of quinupristin-dalfopristin against methicillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of hematogenous pulmonary infection.
    Yanagihara K; Okada M; Fukuda Y; Imamura Y; Kaneko Y; Ohno H; Higashiyama Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
    Chemotherapy; 2004 Nov; 50(5):260-4. PubMed ID: 15528893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.
    Wang FD; Lin ML; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):433-9. PubMed ID: 10925532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of inducible clindamycin resistance in staphylococci: first results from Turkey.
    Azap OK; Arslan H; Timurkaynak F; Yapar G; Oruç E; Gagir U
    Clin Microbiol Infect; 2005 Jul; 11(7):582-4. PubMed ID: 15966979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
    Kang SL; Rybak MJ
    J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.